Arbutus Biopharma (ABUS) to Release Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) is scheduled to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Arbutus Biopharma to post earnings of ($0.10) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Arbutus Biopharma (NASDAQ:ABUS) last issued its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.12). Arbutus Biopharma had a negative return on equity of 57.82% and a negative net margin of 401.57%. The business had revenue of $2.15 million during the quarter, compared to analysts’ expectations of $4.74 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arbutus Biopharma Price Performance

Shares of ABUS opened at $2.75 on Thursday. Arbutus Biopharma has a 12-month low of $1.69 and a 12-month high of $3.29. The business has a 50-day simple moving average of $2.77 and a two-hundred day simple moving average of $2.36. The stock has a market cap of $493.60 million, a PE ratio of -6.25 and a beta of 2.03.

Analysts Set New Price Targets

A number of brokerages have issued reports on ABUS. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 target price on shares of Arbutus Biopharma in a report on Thursday, April 4th. HC Wainwright reduced their price target on Arbutus Biopharma from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 1st. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research report on Friday, March 1st.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.